Related Experiment Video
Updated: May 6, 2026
Strategies for Study of Neuroprotection from Cold-preconditioning
Published on: September 2, 2010
Rifampicin and its neuroprotective properties in humans - A systematic review
Nina Vaezipour1, Sandra Bigi2, Rinn Song3
1Department of Paediatric Infectious diseases and Vaccinology, University Children's Hospital Basel UKBB, Basel, Switzerland; Mycobacterial and Migrant Health Research Group, University of Basel, Basel, Switzerland.
Background:
Rifampicin is an antimicrobial drug used in the treatment of mycobacterial and gram-positive bacterial infections. In vitro studies suggest additional rifampicin-associated reduction of neurotoxicity. The aim of this study was to review the evidence for neuroprotective effects of rifampicin in infectious and non-infectious diseases in human studies.
Methods:
A systematic literature search was done in MEDLINE and Embase including studies from 1 Jan 1946/47-20 Jan 2024, in accordance with the preferred reporting items for systematic reviews and meta-analysis (PRISMA) (PROSPERO ID: CRD42022349852). Original articles investigating the effect of rifampicin on infections of the central nervous system (CNS) or on neurodegenerating diseases, were included. Screening, data extraction and risk of bias assessment were done using the Covidence software. Two authors assessed and extracted articles independently and blinded to each other.
Results:
1438 articles were identified of which eight were included in the final analysis: Four studies included patients with infectious diseases and four studies with neurodegenerative diseases. A neuroprotective effect of rifampicin was shown in five studies. The studies found reduced inflammatory parameters in the cerebrospinal fluid, improved neurological outcome, less cognitive decline, less brain atrophy or less metabolic decline on imaging as an effect of rifampicin. One RCT showed worsening of cognitive assessment scales in neurodegenerative patients.
Conclusion:
Current evidence suggests a neuroprotective effect of rifampicin in humans. As evaluation of neuroprotection is not standardized, a consensus definition for evaluation of clinical, radiological, and neuropsychological follow-up after pharmacological intervention would be helpful for future studies assessing neuroprotection.
Insights
Rifampicin, an antimicrobial drug, shows potential neuroprotective effects in human studies for both infectious and neurodegenerative diseases. Further research is needed to standardize the evaluation of its benefits.
Area of Science:
- Neuroscience
- Pharmacology
- Infectious Diseases
Background:
- Rifampicin is an antimicrobial agent with potential neuroprotective properties suggested by in vitro studies.
- Evidence for rifampicin's neuroprotective effects in human studies across various diseases is being reviewed.
Purpose of the Study:
- To systematically review human studies on the neuroprotective effects of rifampicin.
- To assess rifampicin's impact on both infectious and non-infectious neurological conditions.
Main Methods:
- Systematic literature search of MEDLINE and Embase databases (1946/47-2024).
- Inclusion of original articles on rifampicin's effects on central nervous system (CNS) infections or neurodegenerative diseases.
- Data extraction and risk of bias assessment using Covidence software by two independent reviewers.
Main Results:
- Eight studies were included, with four focusing on infectious diseases and four on neurodegenerative diseases.
- Five studies indicated a neuroprotective effect of rifampicin, evidenced by reduced inflammation, improved neurological outcomes, and less cognitive/metabolic decline.
- One randomized controlled trial (RCT) reported worsened cognitive assessments in neurodegenerative patients.
Conclusions:
- Current evidence suggests rifampicin possesses neuroprotective capabilities in humans.
- Standardized definitions for evaluating clinical, radiological, and neuropsychological outcomes are needed for future neuroprotection studies.
